Nav: Home

Transforming fibrils into crystals

November 08, 2017

Amyloid fibrils are infamous for the role they play in serious neurological diseases in humans, such as Parkinson's or Alzheimer's. One trigger for Alzheimer's disease is the misfolding and aggregation of proteins such as tau and ABeta. This causes the formation of tiny fibrils that then accumulate in the brain. Specialists refer to these fibres as amyloid fibrils.

Raffaele Mezzenga, Professor of Food & Soft Materials at ETH Zurich, has spent a long time studying amyloid fibrils, which he synthesises in the lab starting from non-toxic and edible precursors such as the whey protein component beta-lactoglobulin. He does this by heating the proteins in acid to degrade the original structure; the proteins are "denatured" and become fibrous. Multiple individual strands congregate and twist into a helix to form the mature amyloid fibrils in the lab.

During the process, the whey proteins not only lose their original structure, but also their functionality. In the case of non-toxic food protein precursors, new functionalities are built, which are at the core of an intense research program in the group of Mezzenga.

Transformation of an amyloid fibril

An international team of amyloid experts led by Mezzenga has now made a fundamental discovery with amyloid fibrils generated by fragments of proteins from animal, human and disease related protein sources, made synthetically in the laboratory. The discovery has just been published in Nature Communications.

Under certain circumstances, the fibrils can be transformed into a protein structure that has never been observed before in-vivo and seldom observed in in-vitro studies: an amyloid crystal. The scientists resolve for the first time the physical mechanism by which this transition takes place: this involves untwisting the fibril to form elongated, matchstick-like amyloid crystals without the need to unfold and refold the protein; that is, by simply getting rid of torsional energy associated with the twisted amyloid fibrils.

In the past, researchers had only observed this phenomenon in the test tube but without really being able to identify the mechanisms leading from one structure to another; the amyloid crystals, nonetheless, have never before been found in living cells.

For the research team, it is therefore difficult to say for the time being what implications the discovery will have in the field of amyloid-related diseases. Mezzenga is already sure, however, that the results are significant for protein folding and the formation of amyloid fibrils: "Our results shed new light on the self-organisation of proteins that have a tendency to form amyloids, and on the most stable status of proteins in general."

Nick Reynolds, Research Scientist at Swinburne University of Technology, further believes this work will have major implications in understanding the mechanisms by which amyloid proteins misfold and aggregate in neurodegenerative diseases, eventually leading to the identification of potential new routes for the early diagnosis and treatment of these socioeconomically devastating conditions.

The most stable form of protein

Indeed, once they have formed, the crystals are likely to be the most stable possible form of a protein. This is due to the fact that they have a very low level of internal energy. In terms of the energy landscape, amyloid crystals lie in the deepest valley when compared to other forms of proteins - even lower than amyloid fibrils, which were previously thought to be the lowest-energy and most stable form of protein.

Researchers have statistically and experimentally determined that energy is released when an amyloid fibril transforms into an amyloid crystal. "Our discovery means that the energy landscape of protein folding must now be revisited," says Mezzenga.

Rarely found in nature

Yet the situation is paradoxical from a statistical physics perspective, Mezzenga continues: "If the amyloid crystal represents the lowest possible energy state of a protein form, then most proteins would have to transition to this structure sooner or later." This is due to a well-established principle of statistical thermodynamics that states that in a system with many degrees of freedom, the state of lowest energy is the one most probable and thus most often observed. The same should hold true for proteins, which is why it is astonishing that amyloid crystals have never been found in natural systems such as cells, says Mezzenga.

Mezzenga sees the explanation for this in the fact that cells contain special proteins (chaperones) that assist proteins to fold correctly. This is an energy-intensive process. In the test tube, however, where researchers have managed to produce amyloid crystals directly from amyloid fibril precursors, these enzymes were not present. "Protein-folding in living systems is, after all, much more complex than in the test tube," says Mezzenga.

The fundamental behaviours of amyloid fibrils are is still not entirely understood and somewhat controversial. Mezzenga hopes that his work will help to improve understanding of how proteins with a tendency to form amyloids behave and what is the natural evolution of folded protein conformations in general.

Reynolds NP, Adamcik J, Berryman JT, Handshin S, Hakami Zanjani AA, Li W, Liu K, Zhang A, Mezzenga R. Competition between crystal and fibril formation in molecular mutations of amyloidogenic peptides. Nature Communications, published online 7th Nov 2017. doi:10.1038/s41467-017-01424-4

ETH Zurich

Related Neurodegenerative Diseases Articles:

First 'pathoconnectome' could point toward new treatments for neurodegenerative diseases
Scientists from the John A. Moran Eye Center at the University of Utah have achieved another first in the field of connectomics, which studies the synaptic connections between neurons.
Unlocking the mystery of tau for treatment of neurodegenerative diseases
A team of researchers from various collaborating universities and hospitals in Japan has uncovered crucial molecular details regarding the activity of the ''tau'' protein, promising to revolutionize the therapy of tau-induced neurodegenerative diseases.
Investigational drug stops toxic proteins tied to neurodegenerative diseases
An investigational drug that targets an instigator of the TDP-43 protein, a well-known hallmark of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), may reduce the protein's buildup and neurological decline associated with these disorders, suggests a pre-clinical study from researchers at Penn Medicine and Mayo Clinic.
Inhibition of sphingolipid metabolism and neurodegenerative diseases
Disrupting the production of a class of lipids known as sphingolipids in neurons improved symptoms of neurodegeneration and increased survival in a mouse model.
How understanding the dynamics of yeast prions can shed light on neurodegenerative diseases
How understanding the dynamics of yeast prions can shed light on neurodegenerative diseases
New family of molecules to join altered receptors in neurodegenerative diseases
An article published in the Journal of Medicinal Chemistry shows a new family of molecules with high affinity to join imidazoline receptors, which are altered in the brain of those patients with neurodegenerative diseases such as Alzheimer's, Parkinson's and Huntington's.
Examining diagnoses of stress-related disorders, risk of neurodegenerative diseases
Researchers investigated how stress-related disorders (such as posttraumatic stress disorder, adjustment disorder and stress reactions) were associated with risk for neurodegenerative diseases, including Alzheimer and Parkinson disease and amyotrophic lateral sclerosis (ALS), using data from national health registers in Sweden.
Toxic protein, linked to Alzheimer's and neurodegenerative diseases, exposed in new detail
The protein tau has long been implicated in Alzheimer's and a host of other debilitating brain diseases.
Study uncovers unexpected connection between gliomas, neurodegenerative diseases
New basic science and clinical research identifies TAU, the same protein studied in the development of Alzheimer's, as a biomarker for glioma development.
Neurodegenerative diseases may be caused by transportation failures inside neurons
Protein clumps are routinely found in the brains of patients with neurodegenerative diseases.
More Neurodegenerative Diseases News and Neurodegenerative Diseases Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Warped Reality
False information on the internet makes it harder and harder to know what's true, and the consequences have been devastating. This hour, TED speakers explore ideas around technology and deception. Guests include law professor Danielle Citron, journalist Andrew Marantz, and computer scientist Joy Buolamwini.
Now Playing: Science for the People

#576 Science Communication in Creative Places
When you think of science communication, you might think of TED talks or museum talks or video talks, or... people giving lectures. It's a lot of people talking. But there's more to sci comm than that. This week host Bethany Brookshire talks to three people who have looked at science communication in places you might not expect it. We'll speak with Mauna Dasari, a graduate student at Notre Dame, about making mammals into a March Madness match. We'll talk with Sarah Garner, director of the Pathologists Assistant Program at Tulane University School of Medicine, who takes pathology instruction out of...
Now Playing: Radiolab

What If?
There's plenty of speculation about what Donald Trump might do in the wake of the election. Would he dispute the results if he loses? Would he simply refuse to leave office, or even try to use the military to maintain control? Last summer, Rosa Brooks got together a team of experts and political operatives from both sides of the aisle to ask a slightly different question. Rather than arguing about whether he'd do those things, they dug into what exactly would happen if he did. Part war game part choose your own adventure, Rosa's Transition Integrity Project doesn't give us any predictions, and it isn't a referendum on Trump. Instead, it's a deeply illuminating stress test on our laws, our institutions, and on the commitment to democracy written into the constitution. This episode was reported by Bethel Habte, with help from Tracie Hunte, and produced by Bethel Habte. Jeremy Bloom provided original music. Support Radiolab by becoming a member today at     You can read The Transition Integrity Project's report here.